With more axillary adenopathies likely to present on breast imaging, Society of Breast Imaging experts offer guidance for best management during the pandemic.
In response to evidence published last week in Clinical Imaging that the two approved COVID-19 vaccines can potentially lead to axillary adenopathies that can mimic breast malignancies, the Society of Breast Imaging (SBI) has published management guidelines for affected patients.
Although these adenopathies are rare on normal screening mammograms, appearing on 0.02 percent-to-0.04 percent of studies, SBI experts said, breast imagers need to be aware they will likely be more common in the coming months.
“As national vaccination efforts are underway, women with a recent COVID-19 vaccine may present for diagnostic workup for newly palpable axillary adenopathy or have new axillary adenopathy identified on routine screening mammography or ultrasound,” they said in a published statement, advising breast radiologists they will encounter more axillary adenopathies as vaccine rates increase.
Related Content: COVID-19 Vaccine-Linked Adenopathies Could Mimic Breast Malignancies
According the data from vaccine manufacturers Moderna and Pfizer-BioNTech, these adenopathies can occur in 11.6 percent of patients who receive the first-round vaccine dose and in 16 percent of those who receive the second dose. They appear within two-to-four days and can last for up to 10 days. Post-vaccine adenopathies that have appeared on mammography have, thus far, been unilateral.
To ensure that women undergoing breast imaging are properly managed during this time of the pandemic, the SBI offered five guidelines.
SBI experts cautioned that guidance for assessing and managing these axillary adenopathies could be subject to changes as more information about the COVID-19 vaccines become available. Recommendations for other vaccines will also be incorporated as they are approved for use.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
2 Commerce Drive
Cranbury, NJ 08512